导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.20% | 2105/4773 |
| 近一周 | -2.00% | 3248/5465 |
| 近一月 | -1.11% | 1034/5421 |
| 近一季 | -4.68% | 1869/5231 |
| 近半年 | -8.55% | 3526/4920 |
| 近一年 | 5.24% | 1737/4394 |
| 近两年 | 31.37% | 2225/2954 |
| 近三年 | 21.61% | 1422/2253 |
| 成立以来 | 83.88% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.60% 698/4961 |
1.73% 2996/5312 |
- - |
- - |
| 2025 | 7.33% 2929/4813 |
-4.55% 3197/3635 |
1.14% 2449/4076 |
7.49% 3447/4524 |
3.43% 677/4813 |
| 2024 | 19.52% 522/3463 |
9.63% 123/2808 |
2.11% 399/3014 |
7.78% 2803/3129 |
-0.94% 1549/3463 |
| 2023 | 7.30% 148/2656 |
16.71% 192/2280 |
1.10% 240/2385 |
-3.55% 951/2515 |
-5.70% 1469/2655 |
| 2022 | -12.73% 296/2207 |
-10.90% 451/1919 |
2.64% 1278/2016 |
-9.86% 321/2113 |
5.86% 425/2208 |
| 2021 | 28.43% 81/1822 |
2.97% 203/1255 |
4.05% 929/1330 |
18.61% 62/1466 |
1.06% 1015/1822 |
| 2020 | 11.25% 829/1250 |
-8.18% 591/1028 |
-0.42% 1020/1067 |
9.80% 618/1164 |
10.82% 579/1184 |
| 2019 | - - |
- - |
- - |
- - |
-1.22% 897/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 博时央企创新驱动ETF VS. 长安沪深300非周期A(740101) |